NASDAQ:UROV - Nasdaq -
16.24
+0.01 (+0.06%)
The current stock price of UROV is 16.24 null. In the past month the price increased by 0.43%. In the past year, price increased by 62.89%.
Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom.
Urovant Sciences Ltd
11-12 STREET JAMES SQUARE SUITE 1 3RD FLOOR
LONDON X0 SW1Y 4LB
CEO: James Robinson
Phone: 44-0-20-7400-3347
The current stock price of UROV is 16.24 null. The price increased by 0.06% in the last trading session.
The exchange symbol of Urovant Sciences Ltd is UROV and it is listed on the Nasdaq exchange.
UROV stock is listed on the Nasdaq exchange.
Urovant Sciences Ltd (UROV) has a market capitalization of 531.75M null. This makes UROV a Small Cap stock.
Urovant Sciences Ltd (UROV) has a support level at 16.23 and a resistance level at 16.25. Check the full technical report for a detailed analysis of UROV support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
UROV does not pay a dividend.
Urovant Sciences Ltd (UROV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.14).
ChartMill assigns a technical rating of 7 / 10 to UROV. When comparing the yearly performance of all stocks, UROV turns out to be only a medium performer in the overall market: it outperformed 43.41% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to UROV. UROV has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months UROV reported a non-GAAP Earnings per Share(EPS) of -5.140000000000001. The EPS decreased by -25.06% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -150.35% | ||
ROE | N/A | ||
Debt/Equity | -1.44 |
ChartMill assigns a Buy % Consensus number of 60% to UROV. The Buy consensus is the average rating of analysts ratings from 3 analysts.